PainReform Ltd. (NASDAQ:PRFX) Shares Shorted: Short Interest Down 59.7% in September

PainReform Ltd. (NASDAQ:PRFX – Get Free Report) saw a large decline in short interest in September. As of September 30th, there was short interest totaling 27,647 shares, a decline of 59.7% from the September 15th total of 68,535 shares. Based on an average trading volume of 639,272 shares, the short-interest ratio is currently 0.0 days. Approximately 4.9% of the company’s stock are sold short.

PainReform Price Performance

Shares of PRFX traded down $0.04 during mid-day trading on Tuesday, reaching $0.82. The company’s stock had a trading volume of 43,906 shares, compared to its average volume of 1,217,448. PainReform has a 12-month low of $0.81 and a 12-month high of $7.95. The stock has a market cap of $711,660.00, a PE ratio of -0.00 and a beta of 1.08. The company’s 50 day moving average is $0.98 and its 200 day moving average is $1.47.

Get PainReform alerts:

PainReform (NASDAQ:PRFX – Get Free Report) last issued its earnings results on Thursday, September 3rd. The company reported ($1.13) earnings per share for the quarter. The firm had revenue of $0.01 million during the quarter.

Wall Street Analysts Forecast Growth

A number of equities research analysts have commented on the stock. Wall Street Zen raised shares of PainReform to a “sell” rating in a research report on Saturday, August 1st. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of PainReform in a research report on Friday, July 17th. One analyst has rated the stock with a Sell rating. According to MarketBeat.com, PainReform currently has an average rating of “Sell”.

Get Our Latest Stock Analysis on PRFX

PainReform Company Profile

(Get Free Report)

PainReform Ltd. is a clinical-stage specialty pharmaceutical company focused on developing treatments for acute post-operative pain. The company’s goal is to provide longer-lasting pain relief at the surgical site while potentially reducing reliance on opioid medications after surgery.

PainReform’s lead product candidate, PRF-110, is an investigational extended-release formulation of the local anesthetic ropivacaine. The product is designed to be administered directly into a surgical site and provide pain relief for up to approximately 72 hours following a procedure.

Featured Stories

• Five stocks we like better than PainReform
• A Chinese Rival Just Spooked Memory Stocks—How Worried Should Micron Investors Be?
• Could T-Mobile’s Satellite Competition Fears Create a Buying Opportunity?
• Surgical Precision, Sustainable Returns: Johnson & Johnson Secures Its Cash Flow Runway
• Tesla’s Robotaxi Lands in Paris—But Europe’s Real Fight Is Over Cheap EVs

Receive News & Ratings for PainReform Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PainReform and related companies with MarketBeat.com's FREE daily email newsletter.